Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medicus Pharma Ltd ( (MDCX) ) has provided an update.
Medicus Pharma reported that key opinion leader and principal investigator Dr. Babar Rao has independently validated Phase 2 data for its SkinJect microneedle doxorubicin therapy in nodular basal cell carcinoma. His assessment concludes the dataset is clinically meaningful and supports continued development and regulatory engagement, strengthening confidence in the program’s progression.
The SKNJCT-003 Phase 2 trial showed that the 200µg SkinJect dose achieved about an 80% overall response rate, 73% clinical (visual) clearance, and 40% histological clearance by Day 57, prompting selection of this regimen for further development. Dr. Rao highlighted that visual clearance in roughly three-quarters of lesions could allow many patients to avoid immediate surgery, positioning SkinJect as a potential non-surgical option for patients with limited access to Mohs surgery, high lesion burden, or preference for less invasive treatments.
The most recent analyst rating on (MDCX) stock is a Hold with a $0.48 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily held down by weak financial performance, driven by no revenue, widening operating losses, and sharply increasing cash burn that implies ongoing external funding needs, alongside balance-sheet equity volatility. Technicals are also negative with a strong downtrend (price below all key moving averages and negative MACD), only partially tempered by oversold readings. Valuation metrics provide little support because the P/E is not meaningful and no dividend yield is available.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a precision-guided biotech and life sciences company focused on accelerating the clinical development of novel and potentially disruptive therapeutic assets. The company is advancing SkinJect, a microneedle-mediated doxorubicin delivery platform targeting non-melanoma skin cancers such as nodular basal cell carcinoma, with an emphasis on less invasive alternatives to surgery.
Average Trading Volume: 3,854,591
Technical Sentiment Signal: Sell
Current Market Cap: $17.71M
Learn more about MDCX stock on TipRanks’ Stock Analysis page.